NTRK1 and cancer: Also, it has been suggested that BET inhibition sensitizes PI3K and MYC driven cancer cells to PI3K inhibitor by blocking PI3K pathway reactivation caused by induction and activation of receptor tyrosine kinases (RTKs) through blocking the expression of RTKs45.